Mga Batayang Estadistika
| CIK | 1786255 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Icosavax, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-40655 Icosavax, Inc. (Exact name of registrant as specified in its chart |
|
| February 21, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) ICOSAVAX, INC. (Name of Subject Company (Issuer)) ISOCHRONE MERGER SUB INC. a wholly owned subsidiary of ASTRAZENECA FINANCE AND HOLDINGS INC. a wholly owned subsidiary of ASTRAZENECA PLC (Names of Fi |
|
| February 21, 2024 |
ICVX / Icosavax, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm246819d1sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Icosavax, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchi |
|
| February 21, 2024 |
ICVX / Icosavax, Inc. / Qiming U.S. Healthcare GP II, LLC - SC 13D/A Activist Investment SC 13D/A 1 tm246806d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Icosavax, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 45114M109 (CUSIP Number) Ryan Baker Qiming U.S. Ventures Management, LLC 11100 NE 8th Street, Suite 200 Bell |
|
| February 20, 2024 |
Acquisition of Icosavax Completed Exhibit (a)(5)(H) 19 February 2024 Acquisition of Icosavax Completed AstraZeneca announced today the successful completion of the acquisition of Icosavax, Inc. |
|
| February 20, 2024 |
As filed with the Securities and Exchange Commission on February 20, 2024 As filed with the Securities and Exchange Commission on February 20, 2024 Registration No. |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ICOSAVAX, INC. (Name of Subject Company) ICOSAVAX, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number of Class |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 19, 2024 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (C |
|
| February 20, 2024 |
As filed with the Securities and Exchange Commission on February 20, 2024 As filed with the Securities and Exchange Commission on February 20, 2024 Registration No. |
|
| February 20, 2024 |
FIFTH Amended and Restated CERTIFICATE OF INCORPORATION ICOSAVAX, INC. Exhibit 3.1 FIFTH Amended and Restated CERTIFICATE OF INCORPORATION OF ICOSAVAX, INC. FIRST: The name of the corporation is Icosavax, Inc. (the “Corporation”). SECOND: The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. The name of the Corporation’s registered agent at |
|
| February 20, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) ICOSAVAX, INC. (Name of Subject Company (Issuer)) ISOCHRONE MERGER SUB INC. a wholly owned subsidiary of ASTRAZENECA FINANCE AND HOLDINGS INC. a wholly owned subsidiary of ASTRAZENECA PLC (Names of Fi |
|
| February 20, 2024 |
SECOND AMENDED AND RESTATED BYLAWS ICOSAVAX, INC. ARTICLE I Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF ICOSAVAX, INC. ARTICLE I OFFICES SECTION 1. Registered Office. The registered office of Icosavax, Inc. (the “Corporation”) shall be established and maintained at the office of The Corporation Trust Company, in the City of Wilmington, in the County of New Castle, in the State of Delaware, and said company shall be the registered agent of the Corpora |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ICOSAVAX, INC. (Name of Subject Company) ICOSAVAX, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number of Class |
|
| February 15, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) ICOSAVAX, INC. (Name of Subject Company (Issuer)) ISOCHRONE MERGER SUB INC. a wholly owned subsidiary of ASTRAZENECA FINANCE AND HOLDINGS INC. a wholly owned subsidiary of ASTRAZENECA PLC (Names of Fi |
|
| February 14, 2024 |
ICVX / Icosavax, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243953d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Icosavax, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (the “Shares”) (Title of |
|
| February 14, 2024 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-0799exhibit99.htm JOINT ACQUISITION STATEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity o |
|
| February 14, 2024 |
ICVX / Icosavax, Inc. / Pentwater Capital Management LP - ICOSAVAX, INC. Passive Investment SC 13G 1 p24-0799sc13g.htm ICOSAVAX, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Icosavax, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate b |
|
| January 19, 2024 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ICOSAVAX, INC. (Name of Subject Company) ICOSAVAX, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Numbe |
|
| January 19, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) ICOSAVAX, INC. (Name of Subject Company (Issuer)) ISOCHRONE MERGER SUB INC. a wholly owned subsidiary of ASTRAZENECA FINANCE AND HOLDINGS INC. a wholly owned subsidiary of ASTRAZENECA PLC (Names of Fi |
|
| January 11, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) ICOSAVAX, INC. (Name of Subject Company (Issuer)) ISOCHRONE MERGER SUB INC. a wholly owned subsidiary of ASTRAZENECA FINANCE AND HOLDINGS INC. a wholly owned subsidiary of ASTRAZENECA PLC (Names of |
|
| January 11, 2024 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ICOSAVAX, INC. (Name of Subject Company) ICOSAVAX, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Numbe |
|
| January 10, 2024 |
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County January 10, 2024 Century City Paris Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul VIA EDGAR Hamburg Silicon Valley Hong Kong Singapore Houston Tel Aviv London Tokyo Brian Soares |
|
| December 27, 2023 |
Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| December 27, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ICOSAVAX, INC. (Name of Subject Company (Issuer)) ISOCHRONE MERGER SUB INC. a wholly owned subsidiary of ASTRAZENECA FINANCE AND HOLDINGS INC. a wholly owned subsidiary of ASTRAZENECA PLC (Names of Filing Persons — Off |
|
| December 27, 2023 |
Exhibit 107 Calculation of Filing Fee Table Schedule TO-T (Rule 14d-100) ICOSAVAX, INC. |
|
| December 27, 2023 |
MUTUAL NON-DISCLOSURE AGREEMENT Exhibit (e)(4) MUTUAL NON-DISCLOSURE AGREEMENT This Mutual Non-Disclosure Agreement (this “Agreement”) is entered into between Icosavax, Inc. |
|
| December 27, 2023 |
FIRST AMENDMENT to MUTUAL NON-DISCLOSURE AGREEMENT Exhibit (d)(6) FIRST AMENDMENT to MUTUAL NON-DISCLOSURE AGREEMENT This First Amendment to Mutual Non-Disclosure Agreement (this “Amendment”) is entered into as of November 14, 2023, by and between Icosavax, Inc. |
|
| December 27, 2023 |
Exhibit (a)(1)(C) Offer To Purchase All Outstanding Shares of Common Stock of ICOSAVAX, INC. |
|
| December 27, 2023 |
Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of ICOSAVAX, INC. |
|
| December 27, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ICOSAVAX, INC. (Name of Subject Company) ICOSAVAX, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP |
|
| December 27, 2023 |
Second AMENDMENT to MUTUAL NON-DISCLOSURE AGREEMENT Exhibit (d)(7) Second AMENDMENT to MUTUAL NON-DISCLOSURE AGREEMENT This Second Amendment to Mutual Non-Disclosure Agreement (this “Amendment”) is entered into as of November 26, 2023, by and between Icosavax, Inc. |
|
| December 27, 2023 |
MUTUAL NON-DISCLOSURE AGREEMENT Exhibit (d)(5) MUTUAL NON-DISCLOSURE AGREEMENT This Mutual Non-Disclosure Agreement (this “Agreement”) is entered into as of August 22, 2023 (the “Effective Date”), between Icosavax, Inc. |
|
| December 27, 2023 |
MUTUAL NON-DISCLOSURE AGREEMENT Exhibit (d)(4) MUTUAL NON-DISCLOSURE AGREEMENT This Mutual Non-Disclosure Agreement (this “Agreement”) is entered into between Icosavax, Inc. |
|
| December 27, 2023 |
TABLE OF CONTENTS Exhibit (a)(1)(A) Offer To Purchase All Outstanding Shares of Common Stock of ICOSAVAX, INC. |
|
| December 27, 2023 |
Exhibit (a)(1)(D) Offer To Purchase All Outstanding Shares of Common Stock of ICOSAVAX, INC. |
|
| December 20, 2023 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ICOSAVAX, INC. (Name of Subject Company) ICOSAVAX, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number of Class of Securi |
|
| December 20, 2023 |
Exhibit 99.1 Icosavax, Inc. – Employee Questions and Answers Supplement #1 December 20, 2023 Contents 1. Does Icosavax maintain a severance plan and will it remain in place following closing? 2 2. Who is an eligible employee under the Icosavax severance plan? 2 3. What will trigger a severance event under the Icosavax severance plan? 2 4. What are the severance benefits under the Icosavax seve |
|
| December 14, 2023 |
Exhibit 99.1 Dear [Business Partner], Earlier this week we announced that we have entered into a definitive agreement for Icosavax to be acquired by AstraZeneca. The press release is attached. This is a transformative step in our path to leverage our innovative VLP platform technology to make vaccines that meaningfully impact human health. Icosavax and AstraZeneca have a shared ambition to transfo |
|
| December 14, 2023 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ICOSAVAX, INC. (Name of Subject Company) ICOSAVAX, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number of Class of Securi |
|
| December 12, 2023 |
Subject: Tonight’s announcements EX-99.1 Exhibit 99.1 Subject: Tonight’s announcements Dear Icosahedrons, This evening we made an exciting announcement about a transformative step in our path to leverage our innovative VLP platform technology to make vaccines that meaningfully impact human health. We have entered into a definitive agreement for Icosavax to be acquired by AstraZeneca, which provides an important opportunity to acc |
|
| December 12, 2023 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ICOSAVAX, INC. (Name of Subject Company) ICOSAVAX, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number of Class of Securi |
|
| December 12, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2023 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (C |
|
| December 12, 2023 |
AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln Exhibit 99.5 AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln Reuters 12.12.23 Yadarisa Shabong Dec 12 (Reuters) - AstraZeneca (AZN.L) said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax (ICVX.O) in a deal valued at up to $1.1 billion. Icosavax is developing a combination vaccine candidate targeting RSV and human metapneumovirus (hMPV). RSV i |
|
| December 12, 2023 |
Exhibit 99.2 AstraZeneca LinkedIn post #AstraZenecaBusinessNews #Investors #Media: Today we announced an agreement to acquire Icosavax, Inc., a US-based, clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. Leveraging our expertise in RSV, the acquisition will help us unlock new possi |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ICOSAVAX, INC. (Name of Subject Company — Issuer) ISOCHRONE MERGER SUB INC. a wholly owned subsidiary of ASTRAZENECA FINANCE AND HOLDINGS INC. a wholly owned subsidiary of ASTRAZENECA PLC (Names of Filing Persons — Offe |
|
| December 12, 2023 |
Exhibit 99.1 TENDER AND SUPPORT AGREEMENT THIS TENDER AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of December 11, 2023, by and between AstraZeneca Finance and Holdings Inc., a Delaware corporation (“Parent”), and the undersigned holder (the “Stockholder”) of shares of common stock of Icosavax, Inc., a Delaware corporation (the “Company”). Capitalized terms used herein and |
|
| December 12, 2023 |
Exhibit 99.3 Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca - Icosavax stockholders to receive $15.00 per share in cash at closing plus non-tradeable contingent value right (CVR) of up to $5.00 per share - - Representing a total equity value of up to $1.1 billion including the CVR - SEATTLE, December 11, 2023 — Icosavax, Inc. (Nasdaq: ICVX) today announced it has entered into a d |
|
| December 12, 2023 |
Exhibit 99.1 PUBLISHED 12 December 2023 AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data Building on expertise in RSV prevention, acquisition will accelerate ambition to deliver portfolio of protective interventions to address high unmet needs in infectious diseases AstraZeneca has entered into a definitive agreement t |
|
| December 12, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ASTRAZENECA FINANCE AND HOLDINGS INC., ISOCHRONE MERGER SUB INC. and ICOSAVAX, INC. Dated as of December 11, 2023 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 7 1.1 Certain Definitions 7 1.2 Additional Definitions 19 1.3 Certain Interpretations 21 ARTICLE II THE OFFER 23 2.1 The Offer 23 2.2 Company Actions 27 ARTICLE III THE |
|
| December 12, 2023 |
AstraZeneca strikes $1bn deal to acquire first vaccine company Exhibit 99.4 AstraZeneca strikes $1bn deal to acquire first vaccine company Financial Times 12.12.23 Hannah Kuchler and Donato Mancini AstraZeneca has agreed to buy its first vaccine company in a deal worth up to $1.1bn, as the pharma group expands the infectious disease division it set up during the coronavirus pandemic. The Anglo-Swedish drugmaker said on Tuesday that it had struck a deal for Se |
|
| December 12, 2023 |
EX-99.2 Exhibit 99.2 Icosavax, Inc. – Employee Questions and Answers Contents 1. What was announced regarding Icosavax and AstraZeneca? 1 2. Who is AstraZeneca? 1 3. What is a Tender Offer? 1 4. What will occur in the transaction? What will happen to Icosavax as a company? 2 5. What is the benefit of this acquisition for Icosavax and AstraZeneca, and why was it the best path forward? 2 6. Ho |
|
| December 12, 2023 |
Exhibit 99.2 Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults – IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV, and was generally well tolerated, consistent with prior IVX-A12 Phase 1 data – SEATTLE, December 11, 2023 — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company lev |
|
| December 12, 2023 |
Icosavax buyout caps AstraZeneca’s long search for a vaccine platform Exhibit 99.3 Icosavax buyout caps AstraZeneca’s long search for a vaccine platform ENDPOINTS By Amber Tong 12/12/23 AstraZeneca is gaining a late-stage RSV vaccine candidate as part of its proposed acquisition of Icosavax after the British drugmaker spent two years searching for a platform that would help define the division that encompasses its vaccine and antibodies businesses. The company has b |
|
| December 12, 2023 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ICOSAVAX, INC. (Name of Subject Company) ICOSAVAX, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number of Class of Securi |
|
| November 24, 2023 |
ICVX / Icosavax Inc / ADAMS STREET PARTNERS LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT No. 3 to SCHEDULE 13D/A Under the Securities Exchange Act of 1934 Icosavax, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45114M109 (Cusip Number) Elisha P. Gould III One North Wacker Drive, Suite 2700, Chicago, Illinois 60606 (Name, Address and Telephone Number of Person Authorized to Receive Not |
|
| November 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2023 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (C |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-40655 ICOSAVAX, INC. |
|
| November 14, 2023 |
Exhibit 99.1 Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023 - - Completed candidate selection for SARS-CoV-2 and influenza programs, highlighting company’s antigen de |
|
| August 14, 2023 |
[***] Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT BETWEEN Icosavax, Inc. AND UNIVERSITY OF WASHINGTON FOR Computationally Designed Nanoparticles and Vaccines Based Upon Such Designs uw com |
|
| August 14, 2023 |
EX-99.1 Exhibit 99.1 Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept for revaccination with IVX-121 against RSV - - Initiation of Phase 2 Trial of IVX-A12 with topli |
|
| August 14, 2023 |
Exhibit 10.4 Icosavax, Inc. June 7, 2023 Re: Employment Letter Agreement Dear Amin: Icosavax, Inc. (the “Company”) is pleased to offer you (the “Employee”) a position on the terms set forth in this letter (this “Agreement”). In consideration of the mutual promises herein contained, the parties agree as follows: 1. Commencement of Employment. Employee’s employment with the Company will commence on |
|
| August 14, 2023 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. PUBLIC HEALTH SERVICE Amendment This Agreement is based on the model Amendment Agreement adopted by the U.S. Public Health Service ("PHS") Technology Transfer Policy Board for use by components |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-40655 ICOSAVAX, INC. (Exac |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Com |
|
| August 8, 2023 |
The world needs better vaccines. We’re striving to create them. IVX-121 Phase 1b extension 12-month durability and revaccination update AUG 8, 2023 Exhibit 99.1 Forward looking statements Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company’s current beliefs and expectations |
|
| August 8, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2023 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Comm |
|
| July 25, 2023 |
ICVX / Icosavax Inc / TCG Crossover GP I, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Icosavax, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45114M109 (CUSIP Number) May 25, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| July 25, 2023 |
Exhibit 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| June 13, 2023 |
ICVX / Icosavax Inc / ADAMS STREET PARTNERS LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT No. 2 to SCHEDULE 13D/A Under the Securities Exchange Act of 1934 Icosavax, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45114M109 (Cusip Number) Elisha P. Gould III One North Wacker Drive, Suite 2700, Chicago, Illinois 60606 (Name, Address and Telephone Number of Person Authorized to Receive Not |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2023 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 5, 2023 |
ICVX / Icosavax Inc / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Icosavax, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shares”) (Title of Class of Securities) 45114M109 (CUSIP Num |
|
| June 5, 2023 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Icosavax, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned. Thi |
|
| May 30, 2023 |
ICVX / Icosavax Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Icosavax, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, Addre |
|
| May 23, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266894 PROSPECTUS SUPPLEMENT (To prospectus dated August 29, 2022) 8,369,754 Shares Common Stock We are offering 8,369,754 shares of our common stock in a registered direct offering directly to investors (the Investors) at an offering price of $8.10 per share, pursuant to this prospectus supplement and the accompanying prospec |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2023 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Commis |
|
| May 23, 2023 |
Form of Securities Purchase Agreement. EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 22, 2023, between Icosavax, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2023 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Commis |
|
| May 22, 2023 |
EX-99.1 2 d438524dex991.htm EX-99.1 The world needs better vaccines. We’re striving to create them. IVX-A12 Phase 1 Topline Interim Data | MAY 22, 2023 Exhibit 99.1 Forward looking statements Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company’s current beliefs and expectat |
|
| May 10, 2023 |
EX-99.1 Exhibit 99.1 Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update - IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term investments of $197.7M at end 1Q 2023 - SEATTLE, May 10 2023—Icosavax, Inc. (Nasdaq: ICVX), a biopharm |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-40655 ICOSAVAX, INC. (Exa |
|
| May 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2023 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Commis |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| April 19, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| March 30, 2023 |
EX-99.1 Exhibit 99.1 Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate - - Completed dosing in ongoing Phase 1 study of IVX-A12; topline interim results expected in 2Q 2023 - - Initiation of IVX-A12 Ph |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2023 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Comm |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-40655 ICOSAVAX, INC. (Exact na |
|
| February 14, 2023 |
ICVX / Icosavax, Inc. / NanoDimension III, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Icosavax, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| December 21, 2022 |
ICVX / Icosavax, Inc. / ADAMS STREET PARTNERS LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT No. 1 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Icosavax, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45114M109 (Cusip Number) Elisha P. Gould III One North Wacker Drive, Suite 2700, Chicago, Illinois 60606 (Name, Address and Telephone Number of Person Authorized to Receive Notic |
|
| December 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2022 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (C |
|
| December 13, 2022 |
IVX-121 Ph 1/1b Six-Month Durability Update December 13, 2022 Exhibit 99.1 Forward looking statements Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company?s current beliefs and expectations and include but are not limited to: the potential for the company?s VLP platform to r |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-40655 ICOSAVAX, INC. |
|
| November 14, 2022 |
Exhibit 99.1 Icosavax Reports Third Quarter Financial Results and Provides Corporate Update - Initiated a Phase 1 trial of Icosavax’s first combination bivalent vaccine candidate, IVX-A12, against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults - - IVX-A12 is the first bivalent vaccine candidate against both RSV and hMPV to reach clinical stage development - - Ca |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2022 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (C |
|
| August 25, 2022 |
Icosavax, Inc. 1930 Boren Avenue, Suite 1000 Seattle, WA 98101 Icosavax, Inc. 1930 Boren Avenue, Suite 1000 Seattle, WA 98101 August 25, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Icosavax, Inc. Registration Statement on Form S-3 File No. 333-266894 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Secu |
|
| August 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Icosavax, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate(4) Amount of Registration Fee(4) Fe |
|
| August 16, 2022 |
Exhibit 4.4 ICOSAVAX, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishment of T |
|
| August 16, 2022 |
Exhibit 1.2 ICOSAVAX, INC. $150,000,000 COMMON STOCK EQUITY DISTRIBUTION AGREEMENT August 15, 2022 Oppenheimer & Co. Inc. 85 Broad Street, 26th Floor New York, New York 10004 Ladies and Gentlemen: Icosavax, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Oppenheimer & Co. Inc., as follows: 1. Issuance and Sale of Shares. The Company agrees that, from ti |
|
| August 16, 2022 |
As filed with the Securities and Exchange Commission on August 15, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 15, 2022 Registration No. |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2022 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Com |
|
| August 15, 2022 |
Exhibit 99.1 Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update ? Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - ? Icosavax plans to file an IND and initiate a Phase 1 trial for IVX-A12, a combination bivalent RSV + human metapneumovirus (hMPV) VLP candidate, in 2H 2022 - ? IVX-41 |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-40655 ICOSAVAX, INC. (Exac |
|
| August 15, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Amendment No. 3 to Exclusive License Agreement [***] This amendment number three (?Amendment No. 3?) to the Exclusive License Agreement [***], such agreement effective as of June 29, 2018, as a |
|
| June 28, 2022 |
IVX-121 Phase 1/1b Topline Data June 28, 2022 Exhibit 99.2 Forward looking statements Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company?s current beliefs and expectations and include but are not limited to: the potential for the company?s VLP platform to result in safe an |
|
| June 28, 2022 |
Exhibit 99.1 Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV - IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well tolerated with no vaccine-related SAEs - - Provides initial indication of a differ |
|
| June 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2022 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Commi |
|
| June 15, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2022 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2022 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Commis |
|
| May 16, 2022 |
Exhibit 99.1 Icosavax Reports First Quarter 2022 Financial Results and Provides Corporate Update - Enrollment completed in older adults portion of Phase 1/1b trial of IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Topline, interim Phase 1/1b data for IVX-121 in RSV, including younger and older adults, expec |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-40655 ICOSAVAX, INC. (Exa |
|
| May 16, 2022 |
Icosavax, Inc. Annual Bonus Plan Exhibit 10.1 ICOSAVAX, INC. ANNUAL BONUS PLAN 1. PURPOSE This Annual Bonus Plan (the ?Plan?) is adopted under the Icosavax, Inc. 2021 Incentive Award Plan (the ?2021 Plan?) and is intended to provide an incentive for eligible employees of Icosavax, Inc. (the ?Company?) to perform to the best of their abilities, to further the growth, development and financial success of the Company, and to enable |
|
| April 25, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only |
|
| April 25, 2022 |
The world needs better vaccines. We?re striving to create them. CORPORATE OVERVIEW | APRIL 2022 Exhibit 99.1 Forward looking statements Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company?s current beliefs and expectations and include, but are not limited to: the company?s |
|
| April 25, 2022 |
DEFA14A 1 d349966ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2022 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Comm |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-40655 ICOSAVAX, INC. (Exact na |
|
| March 30, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2022 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Comm |
|
| March 30, 2022 |
Lease Agreement, dated December 15, 2021, by and between Boren Lofts Owner (DE) LLC Exhibit 10.18 BOREN LABS 1930 BOREN AVENUE SEATTLE, WASHINGTON LEASE AGREEMENT BETWEEN BOREN LOFTS OWNER (DE) LLC, a Delaware limited liability company, AS LANDLORD AND ICOSAVAX, INC., a Delaware corporation, AS TENANT |US-DOCS\129492181.2|| TABLE OF CONTENTS Page 1. Basic Lease Information 1 2. Lease Grant 4 3. Term and Commencement Date 6 4. Rent 8 5. Permitted Use; Compliance with Laws 8 6. Let |
|
| March 30, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| March 30, 2022 |
Description of Registered Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Icosavax, Inc. (?we,? ?us? and ?our?) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. Description of Common Stock General The following descri |
|
| March 30, 2022 |
Exhibit 99.1 Icosavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Company anticipates topline, interim data for RSV lead program IVX-121 in 2Q 2022 - - Announced |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 25, 2022 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Comm |
|
| February 28, 2022 |
ICVX / Icosavax, Inc. / Qiming U.S. Healthcare GP II, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Icosavax, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 45114M109 (CUSIP Number) Ryan Baker Qiming U.S. Ventures Management, LLC 888 Seventh Ave, 12th Floor New York, NY 10106 (425) 709-0772 (Name, Address |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2022 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (C |
|
| February 10, 2022 |
ICVX / Icosavax, Inc. / NanoDimension III, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Icosavax, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 8, 2022 |
ICVX / Icosavax, Inc. / Sanofi - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Icosavax, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number) August 2, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| January 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2022 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Com |
|
| January 7, 2022 |
Icosavax Provides Corporate Update and Anticipated Milestones for 2022 Exhibit 99.1 Icosavax Provides Corporate Update and Anticipated Milestones for 2022 SEATTLE, January 7, 2022 ? Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today provided a corporate update and shared anticipated milestones for 2022. Pipeline Updates: ? Exercised o |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2022 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Com |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2021 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (C |
|
| November 18, 2021 |
Exhibit 99.1 Corporate Overview November 2021 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company?s current beliefs and expectations and include, but are not limited to: the company?s expectation regarding the opportunities for, and the therapeuti |
|
| November 18, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 17, 2021 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (C |
|
| November 15, 2021 |
Exhibit 99.1 Icosavax Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Initiated a Phase 1/1b clinical trial for IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Completed dosing in ongoing Phase 1/2 clinical trial for IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 rece |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-40655 ICOSAVAX, INC. |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2021 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (C |
|
| November 15, 2021 |
Exhibit 10.10 Icosavax, Inc. August 9, 2021 Via Email Elizabeth Bekiroglu Re: Employment Letter Agreement Dear Elizabeth: Icosavax, Inc. (the ?Company?) is pleased to offer you (the ?Employee?) a position on the terms set forth in this letter (this ?Agreement?). In consideration of the mutual promises herein contained, the parties agree as follows: 1. Commencement of Employment. Employee?s employm |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission File Number: 001-40655 ICOSAVAX, INC. (Exac |
|
| September 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2021 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) ( |
|
| September 13, 2021 |
Exhibit 99.1 Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain - - Initiated a Phase 1/1b clinical trial for IVX-121, a VLP displaying a Respiratory Syncytial Virus (RSV) stabilized pre-fusion F antigen - - Raised $209.3 million in gro |
|
| August 13, 2021 |
ICVX / Icosavax, Inc. / NanoDimension III, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Icosavax, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number) August 2, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| August 12, 2021 |
ICVX / Icosavax, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Icosavax, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45114M109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, Address and |
|
| August 12, 2021 |
ICVX / Icosavax, Inc. / ADAMS STREET PARTNERS LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Icosavax, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45114M109 (Cusip Number) Elisha P. Gould III One North Wacker Drive, Suite 2700, Chicago, Illinois 60606 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communicatio |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2021 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 2, 2021 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ICOSAVAX, INC. Icosavax, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: 1. The name of the Corporation is Icosavax, Inc. The Corporation was incorporated under the name IcosaVax, Inc. by the filing of its original |
|
| August 2, 2021 |
Exhibit 3.2 Amended and Restated Bylaws of Icosavax, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting. 2 2.5 Notice of Nominations for Election to the Board. 5 |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2021 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40655 82-3640549 (State or other jurisdiction of incorporation or organization) (Comm |
|
| July 30, 2021 |
As filed with the Securities and Exchange Commission on July 30, 2021 As filed with the Securities and Exchange Commission on July 30, 2021 Registration No. |
|
| July 30, 2021 |
12,133,333 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-257733 12,133,333 Shares Common Stock We are offering 12,133,333 shares of our common stock. This is the initial public offering of our common stock. Prior to this offering, there has been no public market for our shares. The initial public offering price is $15.00 per share. Our common stock has been approved for listing on t |
|
| July 28, 2021 |
As filed with the Securities and Exchange Commission on July 28, 2021 As filed with the Securities and Exchange Commission on July 28, 2021 Registration No. |
|
| July 26, 2021 |
[Remainder of page intentionally left blank] Jefferies LLC 520 Madison Avenue New York, New York 10022 Cowen and Company, LLC 599 Lexington Avenue 25th Floor New York, New York 10022 Evercore Group L. |
|
| July 26, 2021 |
Icosavax, Inc. 1616 Eastlake Avenue E., Suite 208 Seattle, WA 98102 Icosavax, Inc. 1616 Eastlake Avenue E., Suite 208 Seattle, WA 98102 July 26, 2021 VIA EDGAR Mr. Alan Campbell Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Icosavax, Inc. Registration Statement on Form S-1 File No. 333-257733 Dear Mr. Campbell Pursuant to Rule 461 of Regulation C of the General Rules and |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ICOSAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 82-3640549 (State of incorporation or organization) (I.R.S. Employer Identification No.) 1616 Eastlake Avenue E., Suit |
|
| July 22, 2021 |
Exhibit 10.16 ICOSAVAX, INC. July 22, 2021 Charles Richardson c/o Icosavax, Inc. Re: Employment Letter Agreement Dear Charles: This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement, dated August 15 2019 (the “Prior Agreement”), by and between Icosavax, Inc. (the “Company”) and you (also referred to herein as “Employee” |
|
| July 22, 2021 |
Exhibit 10.12 ICOSAVAX, INC. July 22, 2021 Adam Simpson c/o Icosavax, Inc. Re: Employment Letter Agreement Dear Adam: This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement, dated August 15, 2019, as amended and restated by that certain employment letter agreement, dated May 11, 2020, as amended by that certain amendmen |
|
| July 22, 2021 |
Amended and Restated Certificate of Incorporation, as amended (currently in effect) Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ICOSAVAX, INC. Icosavax, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name of this corporation is Icosavax, Inc., and that this corporation was originally incorporated pursuant |
|
| July 22, 2021 |
Form of Underwriting Agreement EX-1.1 2 d916073dex11.htm EX-1.1 Exhibit 1.1 [Number of Shares] ICOSAVAX, INC. UNDERWRITING AGREEMENT [Date], 2021 Jefferies LLC Cowen and Company, LLC Evercore Group L.L.C. William Blair & Company, L.L.C. As Representatives of the Several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC 599 Lexington Avenue, 25th Floor New York, New York 10022 |
|
| July 22, 2021 |
Specimen stock certificate evidencing the shares of common stock EX-4.1 4 d916073dex41.htm EX-4.1 Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PO PAR VALUE $0.0001 MR ADD ADD ADD ADD 4 3 2 1 A BOX DESIGNATION SAMPLE Certificate Shares 505006, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Icosavax, Inc. (hereinafter called the “Company”), transferable on the books of the Company in person or by Total DTC dul |
|
| July 22, 2021 |
Exhibit 10.15 ICOSAVAX, INC. July 22, 2021 Cassia Cearley c/o Icosavax, Inc. Re: Employment Letter Agreement Dear Cassia: This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement, dated October 30, 2019, as amended by that certain amendment dated February 8, 2021 (together, the “Prior Agreement”), by and between Icosavax, |
|
| July 22, 2021 |
Exhibit 10.17 ICOSAVAX, INC. July 22, 2021 Thomas J. Russo c/o Icosavax, Inc. Re: Employment Letter Agreement Dear Thomas: This amended and restated employment letter agreement (this ?Agreement?) amends and restates that certain employment letter agreement, dated May 25, 2021 (the ?Prior Agreement?), by and between Icosavax, Inc. (the ?Company?) and you (also referred to herein as ?Employee? and t |
|
| July 22, 2021 |
Power of Attorney of Ann M. Veneman EX-24.2 16 d916073dex242.htm EX-24.2 Exhibit 24.2 POWER OF ATTORNEY I, the undersigned director of Icosavax, Inc., hereby severally constitute and appoint Adam Simpson and Thomas Russo, CFA, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his n |
|
| July 22, 2021 |
Icosavax, Inc. 2021 Employee Stock Purchase Plan Exhibit 10.3 ICOSAVAX, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Component. The Section 423 Component is intended to qualify as |
|
| July 22, 2021 |
Exhibit 10.2 ICOSAVAX, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the Plan are def |
|
| July 22, 2021 |
Exhibit 10.14 ICOSAVAX, INC. July 22, 2021 Niranjan Kanesa-Thasan c/o Icosavax, Inc. Re: Employment Letter Agreement Dear Niranjan: This amended and restated employment letter agreement (this ?Agreement?) amends and restates that certain employment letter agreement, dated August 15, 2019, as amended by that certain amendment dated January 1, 2020, as further amended by that certain amendment dated |
|
| July 22, 2021 |
Exhibit 10.13 ICOSAVAX, INC. July 22, 2021 Douglas Holtzman c/o Icosavax, Inc. Re: Employment Letter Agreement Dear Douglas: This amended and restated employment letter agreement (this ?Agreement?) amends and restates that certain employment letter agreement, dated August 15, 2019 (the ?Prior Agreement?), by and between Icosavax, Inc. (the ?Company?) and you (also referred to herein as ?Employee? |
|
| July 22, 2021 |
As filed with the Securities and Exchange Commission on July 22, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 22, 2021 Registration No. |
|
| July 22, 2021 |
Non-Employee Director Compensation Program Exhibit 10.4 ICOSAVAX, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Icosavax, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatic |
|
| July 16, 2021 |
FOIA CONFIDENTIAL TREATMENT REQUEST FOIA CONFIDENTIAL TREATMENT REQUEST The entity requesting confidential treatment is: Icosavax, Inc. |
|
| July 12, 2021 |
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FOIA CONFIDENTIAL TREATMENT REQUEST The entity requesting confidential treatment is: Icosavax, Inc. [* * *] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested by Icosavax, Inc. with res |
|
| July 7, 2021 |
EX-10.23 20 d916073dex1023.htm EX-10.23 Exhibit 10.23 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GLOBAL ACCESS AND PRICE COMMITMENT AGREEMENT Investment ID [***] This Global Access and Price Commitment Agreement (“Agreement”), effective as of the da |
|
| July 7, 2021 |
Exhibit 10.10 ICOSAVAX, INC. August 15, 2019 Charles Richardson Re: Employment Letter Agreement Dear Charles: In connection with the transactions contemplated by the Series A Preferred Stock Purchase Agreement, dated as of August 15, 2019, by and among the Company and the Purchasers named therein (the “Transaction”), we are amending and restating the terms of your position at Icosavax, Inc. (the “ |
|
| July 7, 2021 |
Icosavax, Inc. 2017 Equity Incentive Plan, as amended and form of stock option agreement thereunder EX-10.1 7 d916073dex101.htm EX-10.1 Exhibit 10.1 ICOSAVAX, INC. 2017 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and |
|
| July 7, 2021 |
Exhibit 10.5 ICOSAVAX, INC. August 15, 2019 Tadataka Yamada Re: Icosavax, Inc. Board of Directors Dear Tachi, In connection with the transactions contemplated by the Series A Preferred Stock Purchase Agreement, dated as of August 15, 2019, by and among the Company and the Purchasers named therein (the “Transaction”), we are amending and restating the terms of your position on the Board of Director |
|
| July 7, 2021 |
Exhibit 3.2 BYLAWS OF ICOSAVAX, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be 251 Little Falls Drive City of Wilmington, County of New Castle, 19808 or in such other location as the Board of Directors may from time to time determine or the business of the corporation may require. Section 2. O |
|
| July 7, 2021 |
Exhibit 10.21 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT NONEXCLUSIVE – SUBLICENSABLE and BIOLOGICAL MATERIALS LICENSE-NON-EXCLUSIVE This Agreement is based on the model Patent License Non-Exclusive Sub |
|
| July 7, 2021 |
EX-4.2 6 d916073dex42.htm EX-4.2 Exhibit 4.2 ICOSAVAX, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT March 19, 2021 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 4 2.2 Company Registration 6 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 7 2.5 Furnish Information 9 2.6 Expenses of Registration 9 2.7 Delay of Registration 9 2.8 Inde |
|
| July 7, 2021 |
Exhibit 3.4 Amended and Restated Bylaws of Icosavax, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting. 2 2.5 Notice of Nominations for Election to the Board. 5 |
|
| July 7, 2021 |
Exhibit 10.8 ICOSAVAX, INC. August 15, 2019 Niranjan Kanesa-thasan, MD MTMH Re: Employment Letter Agreement Dear Niranjan: In connection with the transactions contemplated by the Series A Preferred Stock Purchase Agreement, dated as of August 15, 2019, by and among the Company and the Purchasers named therein (the ?Transaction?), we are amending and restating the terms of your position at Icosavax |
|
| July 7, 2021 |
Exhibit 10.7 ICOSAVAX, INC. August 15, 2019 Douglas A. Holtzman Re: Employment Letter Agreement Dear Douglas: In connection with the transactions contemplated by the Series A Preferred Stock Purchase Agreement, dated as of August 15, 2019, by and among the Company and the Purchasers named therein (the “Transaction”), we are amending and restating the terms of your position at Icosavax, Inc. (the “ |
|
| July 7, 2021 |
Employment Letter Agreement, dated May 25, 2021, by and between Thomas J. Russo and the Registrant Exhibit 10.11 ICOSAVAX, INC. May 25, 2021 Thomas J. Russo Re: Employment Letter Agreement Dear Thomas: Icosavax, Inc. (the ?Company?) is pleased to offer you (the ?Employee?) a position on the terms set forth in this letter (this ?Agreement?). In consideration of the mutual promises herein contained, the parties agree as follows: 1. Commencement of Employment. Employee?s employment with the Compan |
|
| July 7, 2021 |
Exhibit 10.22 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GRANT AGREEMENT Investment ID [***] AGREEMENT SUMMARY & SIGNATURE PAGE GRANTEE INFORMATION Name: Icosavax, Inc. Tax Status: Not exempt from federal income tax under U.S. IRC § 501(c)(3) You co |
|
| July 7, 2021 |
Exhibit 10.24 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Patent License Agreement Agreement No. [***] This Patent License Agreement is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”). No binding a |
|
| July 7, 2021 |
Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ICOSAVAX, INC. Icosavax, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is Icosavax, Inc. The Corporation was incorporated under the name IcosaVax, Inc. by the filing of its original |
|
| July 7, 2021 |
Exhibit 10.6 ICOSAVAX, INC. May 11, 2020 Adam Simpson Re: Employment Letter Agreement Dear Adam: This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement, dated August 15, 2019 (the “Prior Agreement”), by and between the Company and you (also referred herein as “Employee” and together, the “Parties”). This Agreement sets |
|
| July 7, 2021 |
Form of Indemnification Agreement for Directors and Officers Exhibit 10.18 INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of , 20 by and between Icosavax, Inc., a Delaware corporation (the ?Company?), and , [a member of the Board of Directors/ an officer] of the Company (?Indemnitee?). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and adva |
|
| July 7, 2021 |
Exhibit 10.19 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT BETWEEN ICOSAVAX, INC. AND UNIVERSITY OF WASHINGTON FOR COMPUTATIONALLY DESIGNED NANOPARTICLES AND VACCINES BASED UPON SUCH DESIGNS UW COMOTION AGREEMENT REF. [***] |
|
| July 7, 2021 |
EX-10.20 17 d916073dex1020.htm EX-10.20 Exhibit 10.20 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AND EXCLUSIVE OPTION AGREEMENT BETWEEN ICOSAVAX, INC. AND UNIVERSITY OF WASHINGTON FOR COMPUTATIONALLY DESIGNED NANOPARTICLES AND VACCINES BASED |
|
| July 7, 2021 |
Power of Attorney (included on signature page) Table of Contents As filed with the Securities and Exchange Commission on July 6, 2021 Registration No. |
|
| July 7, 2021 |
Amended and Restated Certificate of Incorporation, as amended EX-3.1 2 d916073dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ICOSAVAX, INC. Icosavax, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That the name of this corporation is Icosavax, Inc., and that this corporation was |
|
| July 7, 2021 |
Exhibit 10.9 ICOSAVAX, INC. February 8, 2021 Cassia Cearley Re: Amended and Restated Employment Letter Agreement Dear Cassia: We are amending and restating the terms of your position at Icosavax, Inc. (the ?Company?), as previously set forth in that certain Employment Letter Agreement, dated October 30, 2019 (the ?Prior Agreement?), by and between the Company and you (the ?Employee?). In considera |
|
| July 6, 2021 |
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh July 6, 2021 VIA EDGAR Mr. Alan Campbell Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission D?sseldorf San Diego Frankfurt Sa |
|
| June 21, 2021 |
Exhibit 10.17 ICOSAVAX, INC. May 25, 2021 Thomas J. Russo Re: Employment Letter Agreement Dear Thomas: Icosavax, Inc. (the ?Company?) is pleased to offer you (the ?Employee?) a position on the terms set forth in this letter (this ?Agreement?). In consideration of the mutual promises herein contained, the parties agree as follows: 1. Commencement of Employment. Employee?s employment with the Compan |
|
| June 21, 2021 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on June 17, 2021 as Amendment No. |
|
| June 21, 2021 |
Patent License Agreement Agreement No. [***] EX-10.18 3 filename3.htm Exhibit 10.18 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Patent License Agreement Agreement No. [***] This Patent License Agreement is between the Licensor and the Licensee identified below (collectively, “Parties”, or singl |
|
| June 17, 2021 |
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh June 17, 2021 D?sseldorf San Diego Frankfurt San Francisco VIA EDGAR Hamburg Seoul Hong Kong Shanghai Mr. Alan Campbell Houston Silicon Valley Office of Life Sciences Lon |
|
| May 14, 2021 |
EX-10.5 6 filename6.htm Exhibit 10.5 ICOSAVAX, INC. August 15, 2019 Tadataka Yamada Re: Icosavax, Inc. Board of Directors Dear Tachi, In connection with the transactions contemplated by the Series A Preferred Stock Purchase Agreement, dated as of August 15, 2019, by and among the Company and the Purchasers named therein (the “Transaction”), we are amending and restating the terms of your position |
|
| May 14, 2021 |
EX-10.9 10 filename10.htm Exhibit 10.9 ICOSAVAX, INC. February 8, 2021 Cassia Cearley Re: Amended and Restated Employment Letter Agreement Dear Cassia: We are amending and restating the terms of your position at Icosavax, Inc. (the “Company”), as previously set forth in that certain Employment Letter Agreement, dated October 30, 2019 (the “Prior Agreement”), by and between the Company and you (the |
|
| May 14, 2021 |
ICOSAVAX, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT March 19, 2021 EX-4.2 4 filename4.htm Exhibit 4.2 ICOSAVAX, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT March 19, 2021 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 4 2.2 Company Registration 6 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 7 2.5 Furnish Information 9 2.6 Expenses of Registration 9 2.7 Delay of Registration 9 2.8 Indemnificatio |
|
| May 14, 2021 |
EX-10.8 9 filename9.htm Exhibit 10.8 ICOSAVAX, INC. August 15, 2019 Niranjan Kanesa-thasan, MD MTMH Re: Employment Letter Agreement Dear Niranjan: In connection with the transactions contemplated by the Series A Preferred Stock Purchase Agreement, dated as of August 15, 2019, by and among the Company and the Purchasers named therein (the “Transaction”), we are amending and restating the terms of y |
|
| May 14, 2021 |
GRANT AGREEMENT Investment ID [***] AGREEMENT SUMMARY & SIGNATURE PAGE EX-10.15 15 filename15.htm Exhibit 10.15 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GRANT AGREEMENT Investment ID [***] AGREEMENT SUMMARY & SIGNATURE PAGE GRANTEE INFORMATION Name: Icosavax, Inc. Tax Status: Not exempt from federal income tax under |
|
| May 14, 2021 |
GLOBAL ACCESS AND PRICE COMMITMENT AGREEMENT Investment ID [***] EX-10.16 16 filename16.htm Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. GLOBAL ACCESS AND PRICE COMMITMENT AGREEMENT Investment ID [***] This Global Access and Price Commitment Agreement (“Agreement”), effective as of the date of the las |
|
| May 14, 2021 |
As confidentially submitted to the Securities and Exchange Commission on May 14, 2021 Table of Contents As confidentially submitted to the Securities and Exchange Commission on May 14, 2021 Registration No. |
|
| May 14, 2021 |
EX-10.7 8 filename8.htm Exhibit 10.7 ICOSAVAX, INC. August 15, 2019 Douglas A. Holtzman Re: Employment Letter Agreement Dear Douglas: In connection with the transactions contemplated by the Series A Preferred Stock Purchase Agreement, dated as of August 15, 2019, by and among the Company and the Purchasers named therein (the “Transaction”), we are amending and restating the terms of your position |
|
| May 14, 2021 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ICOSAVAX, INC. EX-3.1 2 filename2.htm Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ICOSAVAX, INC. Icosavax, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That the name of this corporation is Icosavax, Inc., and that this corporation was originally |
|
| May 14, 2021 |
EX-10.6 7 filename7.htm Exhibit 10.6 ICOSAVAX, INC. May 11, 2020 Adam Simpson Re: Employment Letter Agreement Dear Adam: This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement, dated August 15, 2019 (the “Prior Agreement”), by and between the Company and you (also referred herein as “Employee” and together, the “Parties |
|
| May 14, 2021 |
ICOSAVAX, INC. 2017 EQUITY INCENTIVE PLAN EX-10.1 5 filename5.htm Exhibit 10.1 ICOSAVAX, INC. 2017 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby bett |
|
| May 14, 2021 |
BYLAWS ICOSAVAX, INC. (A DELAWARE CORPORATION) EX-3.2 3 filename3.htm Exhibit 3.2 BYLAWS OF ICOSAVAX, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be 251 Little Falls Drive City of Wilmington, County of New Castle, 19808 or in such other location as the Board of Directors may from time to time determine or the business of the corporation ma |
|
| May 14, 2021 |
EX-10.12 12 filename12.htm Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT BETWEEN ICOSAVAX, INC. AND UNIVERSITY OF WASHINGTON FOR COMPUTATIONALLY DESIGNED NANOPARTICLES AND VACCINES BASED UPON SUCH DESIGNS UW CO |
|
| May 14, 2021 |
EX-10.10 Exhibit 10.10 ICOSAVAX, INC. August 15, 2019 Charles Richardson Re: Employment Letter Agreement Dear Charles: In connection with the transactions contemplated by the Series A Preferred Stock Purchase Agreement, dated as of August 15, 2019, by and among the Company and the Purchasers named therein (the “Transaction”), we are amending and restating the terms of your position at Icosavax, In |
|
| May 14, 2021 |
EX-10.13 13 filename13.htm Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AND EXCLUSIVE OPTION AGREEMENT BETWEEN ICOSAVAX, INC. AND UNIVERSITY OF WASHINGTON FOR COMPUTATIONALLY DESIGNED NANOPARTICLES AND VACCINES BASED UPON SUCH DE |
|
| May 14, 2021 |
EX-10.14 14 filename14.htm Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT NONEXCLUSIVE – SUBLICENSABLE and BIOLOGICAL MATERIALS LICENSE-NON-EXCLUSIVE This Agreement is based on the model Paten |
